0000899243-22-005320.txt : 20220208
0000899243-22-005320.hdr.sgml : 20220208
20220208213053
ACCESSION NUMBER: 0000899243-22-005320
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220204
FILED AS OF DATE: 20220208
DATE AS OF CHANGE: 20220208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ege David S.
CENTRAL INDEX KEY: 0001829360
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 22603606
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-04
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001829360
Ege David S.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Stock Option (Right to Buy)
7.38
2022-02-04
4
A
0
175000
0.00
A
2032-02-03
Common Stock
175000
175000
D
The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Executive Vice President and Chief Technology Officer
/s/ Thomas J. DesRosier, attorney-in-fact for David Ege
2022-02-08